- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Contact us
- Thank you
XVIVO Perfusion AB admitted to trading on Nasdaq First North Premier
As previously announced, XVIVO Perfusion AB (publ) (the "Company" or " Xvivo Perfusion ") has decided to apply for listing of XVIVO Perfusion’s shares on Nasdaq First North Premier as part of preparing the company for listing on the Nasdaq Stockholm's main list. Nasdaq has approved the Company's application and the first day of trading in XVIVO Perfusion’s shares on Nasdaq First North Premier will be 8 February 2016. The company's shares will continue trading with the same short name and ISIN code.
February 5, 2016
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, email@example.com
Magnus Nilsson, CEO, +46 31 788 2150, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on February 5, 2016 at 4:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.